Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Fisetin wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Likely helps
3 of 3 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Dasatinib and Fisetin have evidence — compare verdict strength side-by-side.
No validated longevity dose. Senolytic research uses intermittent 'hit-and-run' D+Q (e.g. dasatinib 100 mg + quercetin for ~2–3 days, repeated periodically) — investigational and only appropriate under medical supervision. Approved leukemia dosing is continuous and higher.
any
Oral dasatinib + quercetin (D+Q)
100-500mg (intermittent dosing for senolytic effect)
With meals containing fat
Fisetin capsules or powder
Unknown in humans
Days to weeks (pilot data)
During exposure
Unknown in humans (animal data only)
4-8 weeks (limited evidence)
Senolytics improve physical function and increase lifespan in old age.
Nature medicine (2018) · Animal
Dasatinib + quercetin (and other senolytics) improved physical function and survival in aged mice
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.
EBioMedicine (2019) · Open label · n=14
First-in-human open-label pilot of D+Q in idiopathic pulmonary fibrosis
Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.
EBioMedicine (2019) · Pilot
Open-label pilot of D+Q in diabetic kidney disease
Supplement and nutraceutical therapy in traumatic brain injury
Nutritional neuroscience (2025) · Systematic review
Nutraceuticals and supplements show promising potential in the management of TBI.Trial registration: ClinicalTrials.gov identifier: NCT01814527.Trial registration: ClinicalTrials.gov identifier: NCT03032302.
Polyphenols in the Prevention and Treatment of Colorectal Cancer: A Systematic Review of Clinical Evidence
Nutrients (2024) · Systematic review · n=100
Curcumin demonstrated promise in various trials, mainly decreasing inflammatory cytokines, though results varied, and it did not lower intestinal adenomas or improve outcomes after chemotherapy.
Selected Flavonols in Breast and Gynecological Cancer: A Systematic Review
Nutrients (2023) · Systematic review
The consumption of foods that are rich in phenolic compounds has chemopreventive effects on many cancers, including breast cancer, ovarian cancer, and endometrial cancer.
Based primarily on one RCT with exercise intervention (n=60) and systematic reviews without dose-specific data. Long-term safety unclear. Bioavailability highly dependent on formulation - standard fisetin has poor absorption.
AI-estimated from published studies. Interpret as directional guidance.
Fisetin has a higher evidence score (3.5/10 vs 3.5/10) and wins in 2 of 3 categories.
No known interactions between Dasatinib and Fisetin have been documented in our database. However, always consult a healthcare provider before combining supplements.